1/1

Continuous subcutaneous insulin infusion: national and international scenario

dataset
posted on 26.12.2018 by Dayane Silveira, Tamara Angelo, Rafael Mota Pinheiro, Taís Gratieri

Abstract Introduction The Continuous Subcutaneous Insulin Infusion pump system (CSII) is an alternative to multiple daily administration of insulin in diabetic patients. Although it has many advantages, its availability in the public health system is still very low. This study aimed to identify practices and experiences of health departments and organizations on the use of CSII. Method Questionnaires were applied to Brazilian Health Departments of the States (SES) and international organizations for health technologies evaluation. Results Most of the SES (83%) have received lawsuits and the use of CSII has increased in the last 5 years. International organizations reported that in 47% of countries, the CSII is available to patients through the public health system. Conclusion The use of CSII brings several benefits, but also a high annual additional cost of approximately R$ 9,500 per patient. Therefore, there is an evident need to conduct studies assessing the incorporation of CSII, its budgetary impact in the Brazilian health system, and the definition of which circumstances this will be made available to the population.

History

Licence

Exports